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Objective: To assess the immunomodulatory activity of methylthioadenosine (MTA) in rodent experimental autoimmune en-
cephalomyelitis (EAE) and in patients with multiple sclerosis.
Methods: We studied the effect of intraperitoneal MTA in the acute and chronic EAE model by quantifying clinical and
histological scores and by performing immunohistochemistry stains of the brain. We studied the immunomodulatory effect of
MTA in lymphocytes from EAE animals and in peripheral blood mononuclear cells from healthy control subjects and multiple
sclerosis patients by assessing cell proliferation and cytokine gene expression, by real-time polymerase chain reaction, and by
nuclear factor-B modulation by Western blot.
Results: We found that MTA prevents acute EAE and, more importantly, reverses chronic-relapsing EAE. MTA treatment
markedly inhibited brain inflammation and reduced brain damage. Administration of MTA suppressed T-cell activation in vivo
and in vitro, likely through a blockade in T-cell signaling resulting in the prevention of inhibitor of kappa B (IB-) degra-
dation and in the impaired activation transcription factor nuclear factor-B. Indeed, MTA suppressed the production of proin-
flammatory genes and cytokines (interferon-, tumor necrosis factor-, and inducible nitric oxide synthase) and increased the
production of antiinflammatory cytokines (interleukin-10).
Interpretation: MTA has a remarkable immunomodulatory activity and may be beneficial for multiple sclerosis and other
autoimmune diseases.
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Methylthioadenosine (MTA) is a lipophilic sulfur-
containing adenine nucleoside produced from
S-adenosylmethionine, during the synthesis of the
polyamines spermine and spermidine.1 Besides its
strong inhibitory effect on the polyamine biosynthesis,
MTA has been shown to exert other potent and spe-
cific pharmacological effects on cellular function, such
as control of hepatocellular proliferation, inhibition of
the development of neoplastic liver lesions, protection
from toxic liver injury, and modulation of the inflam-
matory response.2 Indeed, we have recently reported
that MTA prevented bacterial lipopolysaccharide
(LPS)-induced lethality in mice, likely through the
suppression of tumor necrosis factor- (TNF-) pro-
duction and inducible nitric oxide synthase (iNOS)
gene expression and by enhancing the expression of
interleukin-10 (IL-10).3
Multiple sclerosis (MS) is an autoimmune disease af-
fecting two million people around the world, mainly in
well-developed countries.4 MS represents a significant
health and social burden because it affects young
adults, many of whom suffer a significant disability,
and because the cost of years with the disease is high.
MS is diagnosed when only minor central nervous sys-
tem (CNS) damage has already occurred, which sug-
gests that if we stop the inflammatory process at the
early phase of the disease, we can prevent most of the
brain damage and future disability. Although in recent
years it has been stressed that the progressive phase of
MS can be considered a neurodegenerative process,
even during this chronic phase, the major cause of ax-
onal damage appears to be related to the immunopa-
thology secondary to the autoimmune process.5 Thus,
controlling the autoimmune response into the brain
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might be highly efficacious in preventing brain tissue
damage and increase of disability, and may reduce the
risk for progression toward the neurodegenerative phase.
Currently approved therapies for MS are immuno-
modulatory drugs, such as interferon- (IFN-) and
glatiramer acetate, which are only partly effective, are
administered parentally, and are often limited by side
effects.6 Close to 40% of patients are considered non-
responders,7–9 and their disease continuously progresses
leading to significant disability. Thus, the discovery of a
new immunomodulatory agent that improves the con-
trol of the disease, which might be suitable and safe for
polytherapy and for oral administration, will be of great
medical interest. Here, we report that the small molecule
MTA is an immunomodulatory compound able to pre-
vent acute experimental autoimmune encephalomyelitis
(EAE), but more important, it is able to ameliorate
chronic-relapsing EAE by suppressing the T-cell activa-
tion process. Thus, MTA might be an effective therapy
for treating MS and other autoimmune diseases.
Subjects and Methods
Patients
We studied 13 patients with MS fulfilling McDonald crite-
ria.10 They were 10 female and 3 male patients aged 46 
13 years old, with a disease duration of 14.1  14 years,
moderate disability (Expanded Disability Status Scale 
3.0  1.4, range, 0–6.0; Multiple Sclerosis Functional
Composite  0.31  0.43), and the following disease sub-
types: 7 relapsing-remitting MS, 3 secondary progressive MS,
2 progressive-relapsing MS, and 1 primary progressive MS.
Only three relapsing-remitting MS patients had undergone
immunomodulatory therapy (IFN-) at the time of the
study. We also studied 10 healthy donors (6 female and 4
male donors; mean age, 37  13 years). All patients were
stable at time of assessment, and none were suffering a clin-
ical relapse. Patients’ consent was obtained according to the
Declaration of Helsinki, and the study was approved by the
ethical committee of University of Navarra.
Animals, Experimental Autoimmune
Encephalomyelitis Induction, and Treatment
Studies were approved by the University of Navarra Com-
mittee on Animal Care. Female Lewis rats from Charles
River or Dark Agouti (DA) rats from Harlan (6–8 weeks
old; 175–200gm body weight) were immunized in both hind
pads with 100l of an emulsion of saline and incomplete
Freund’s adjuvant containing 75g guinea pig myelin basic
protein fragment 68-82 (Sigma, St. Louis, MO) or 100g
recombinant rat myelin oligodendrocyte glycoprotein (puri-
fied in our laboratory as described previously11) and supple-
mented with 4mg/ml Mycobacterium tuberculosis (H37Ra
strain; Difco, Detroit, MI). Animals were weighed and in-
spected for clinical signs of disease on a daily basis by a
blinded observer. Disease severity of EAE was assessed ac-
cording to the following scale: 0  normal; 0.5  mild limp
tail; 1  limp tail; 2  mild paraparesis of the hind limbs,
unsteady gait; 3  moderate paraparesis, voluntary move-
ments still possible; 4  paraplegia or tetraparesis; 5  mor-
ibund state. Data shown for the clinical studies in acute EAE
and chronic-relapsing EAE are representative of three and
two independent experiments performed with the indicated
number of animals, respectively.
MTA was prepared from S-adenosylmethionine (Europ-
harma, Madrid, Spain) as described elsewhere.12 Animals
were treated with MTA (96mol/kg body weight) or pla-
cebo (tris[hydroxymethyl]aminomethane buffer 100mM, pH
7.0) through daily intraperitoneal injection starting after im-
munization in the prevention trial (acute EAE) or after the
end of the first relapse in the treatment trial (chronic-
relapsing EAE). MTA dose was based on our previous expe-
rience treating LPS-induced mortality in mice.3 At the end
of the study, rats were anesthetized and perfused intracardia-
cally with 4% paraformaldehyde in 0.1M phosphate buffer
(pH 7.6). Brains, spinal cord, and spleens were dissected and
either fixed or frozen until use. Serum was obtained from all
animals included in the study, and transaminases levels (ala-
nine and aspartate aminotransferase) were measured. No sig-
nificant differences in serum transaminases levels were ob-
served between the different groups of animals at the end of
the study.
Real-time Quantitative Polymerase Chain Reaction
Splenocytes from Lewis and DA rats obtained at the time of
death were homogenized in RNA lysis buffer. Total RNA
from rat splenocytes or human peripheral blood mononu-
clear cells (PBMCs) was extracted using the RNeasy Mini
Kit (Qiagen, Chatsworth, CA) isolation system, including
DNase treatment using the RNase-Free DNase Set (Qiagen).
Total RNA (35g) was reverse transcribed using the Reverse
Transcription System (High Capacity cDNA Archive Kit;
Applied Biosystems, Foster City, CA). The real-time reaction
was conducted at 25°C for 10 minutes, followed by 37°C for
2 hours, and finally stored at 4°C. Primers and target-specific
fluorescence-labeled TaqMan probes were purchased from
Applied Biosystems (TaqMan Gene Expression Assays). We
used the TaqMan Universal Master Mix (Applied Biosys-
tems). Amplification of complementary DNA was performed
on a DNA Engine Opticon 2 Real-Time System (MJ Re-
search, Watertown, MA) using 0.9M for each primer and
0.25M for the probe and 20ng complementary DNA. The
reaction conditions were an initial 2 minutes at 50°C, fol-
lowed by 10 minutes at 95°C and 40 cycles of 15 seconds at
95°C and 1 minute at 60°C. Each sample was run in tripli-
cate, and in each plate the target and the endogenous control
were amplified in different wells. The expression of the dif-
ferent genes tested was quantified relative to the level of the
housekeeping gene 18S rRNA.
Immunohistochemistry
Histological evaluation was done on paraformaldehyde-fixed,
paraffin-embedded sections of brain and spinal cord. Sec-
tions (10 m thick) were stained with hematoxylin and eosin
and Luxol fast blue to assess inflammation and demyelina-
tion. We examined 20 consecutive sagittal sections from ev-
ery region examined (brain, cervical, thoracic, and lumbar
spinal cord) per rat for all animals of the study. Semiquan-
titative histological evaluation for inflammation and demyeli-
324 Annals of Neurology Vol 60 No 3 September 2006
nation was conducted and scored blindly using the following
scale: 0  normal; 1  1 to 3/section perivascular cuffs with
minimal demyelination; 2  3 to 10 perivascular cuffs/sec-
tion accompanied by moderate demyelination; 3  wide-
spread perivascular cuffing, extensive demyelination with
large confluent lesions.11
Immunohistochemical procedures were performed on
10m paraffin-embedded sections of brain and spinal cord
as described previously.11 Primary antibodies were added at
the following dilutions: polyclonal rabbit anti–glial fibrillary
acidic protein antibody, 1:1,000 (Dakocitomation, Glostrup,
Denmark); mouse anti-amyloid -precursor protein (APP)
antibody, 1:100 (Zymed Laboratories, San Francisco, CA);
mouse anti I-A (OX-6) antibody, 1:200 (Serotec, Bicester,
United Kingdom); mouse anti–rat CD8 antibody, 1:250 (Se-
rotec); iNOS antibody, 1:250 (Serotec); mouse anti–rat
CD68 (ED1) antibody, 1:200 (Serotec); and mouse anti–rat
CD43 (W3/13) antibody, 1:50 (Serotec). The specificity of
the immunoreaction was determined by incubating sections
without the primary antibodies or using the corresponding
isotype controls (rabbit and mouse IgG; Vector Laboratories,
Burlingame, CA), which yielded no immunoreactivity. Im-
munohistochemical findings were quantitated based on the
average number of positively labeled cells per section. In
brief, scores were determined by a blinded observer using the
following scale: negative, no positive cells; , rare, less than 5
positive cells/10	 magnified microscope field; , 5 to 20
positive cells/10x	magnified microscope field; , more
than 20 positive cells/10	 magnified microscope field.13
In Vitro Immunological Studies
Human PBMCs and rat splenocytes from MTA- (n  20)
and placebo-treated (n  27) Lewis rats were isolated by
Ficoll Hypaque density centrifugation (Pharmacia, Gaithers-
burg, MD). In addition, splenocytes from naive, nonimmu-
nized Lewis rats were obtained for in vitro assessment of the
effect of MTA in cell proliferation. Splenocyte proliferation
assay was performed as described previously.11 Phytohemag-
glutinin (PHA), 3
-deazaadenosine (DZA) and adenosine-2-
3-dialdehyde (AdOx), forskolin, and H89 were obtained
from Sigma. At the end of all experiments, cellular viability
was assessed by the trypan blue exclusion test as described
previously,3 and no significant differences were observed
among the different treatments (always 95% cell viability).
Cell viability also was examined by the determination of lac-
tate dehydrogenase (LDH) activity in the culture medium at
the end of each experiment, using the Cytotox 96 assay (Pro-
mega, Madison, WI). There were no significant differences
in LDH activity between control cultures and the different
treatments. LDH activity in the culture medium never ex-
ceeded 5% of total LDH activity, determined after total cell
lysis by incubation with 1% Triton X-100 (Sigma) for 10
minutes at 37°C.
Western Blot Analysis
After the indicated treatments, PBMCs cells were lysed and
Western blots were performed as described previously.14 Im-
munodetection of inhibitor kappa B- (IB-) and Ser-32
phosphorylated IB- was performed using the correspond-
ing antibodies (sc-371 [Santa Cruz, Santa Cruz, CA] and
9241S [Cell Signaling Technology, Beverly, MA]). Equal
loading of the gels and specificity of the effects were demon-
strated by hybridizing membranes with an antibody specific
for actin (Calbiochem-Novabiochem, Darmstadt, Germany).
Statistical Analysis
Statistical analyses were performed with the two-tailed
Mann–Whitney U test for comparing EAE scores, 2 test for
comparing disease incidence, Kaplan–Meier curves for differ-
ences in day of onset of acute EAE or differences in the onset
of the second relapse in chronic-relapsing EAE, and contin-
gency tables with Kendal’s tau test for histological score com-
parison. p values less than 0.05 were considered to indicate a
significant difference. The statistical evaluation was con-
ducted using the SPSS 11.0 statistical program (SPSS, Chi-
cago, IL).
Results
Methylthioadenosine Prevents Acute Experimental
Autoimmune Encephalomyelitis in Lewis Rats
Beginning the same day as induction of EAE, Lewis
rats were randomly assigned to treatment with daily
MTA or placebo and assessed blindly. All but one of
the placebo-treated animals developed neurological
symptoms of acute EAE, consisting of progressive
weight loss, limp tail, and mild-to-moderate parapare-
sis. First neurological symptoms were observed at day
12 with mean day of onset 13.4  0.8 (n  27). The
maximum score individual animals reached during the
time course of the experiment was 1.75  0.41 (Table
1). By contrast, MTA-treated rats (n  20) showed
either no clinical signs or a markedly attenuated disease
course, with lower disease incidence (5/20; p  0.005)
and lower maximum clinical scores (0.10  0.21) with
Table 1. Results of the Prevention Trial (Acute Experimental Autoimmune Encephalomyelitis in Lewis Rats)
Treatment Rats, n
EAE
Incidence
EAE
Onset
(days)
EAE
Maximum
Score
EAE Cumulative
Score
MTA 20 5/20 14.5 1.2 0.10 0.21 2.5 0.07
Placebo 27 26/27a 13.4 0.8 1.75  0.41a 134.5 4a
Results are the sum of three different experiments.
ap  0.005, comparison of either methylthioadenosine (MTA)-treated group with placebo-treated group.
EAE  experimental autoimmune encephalomyelitis.
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respect to the placebo group (p  0.005) (see Table 1;
Fig 1A). These results are the sum of three different
experiments.
Histological evaluation confirmed the observed clin-
ical protection (see Fig 1B and Table 2). In MTA-
treated rats, the number and size of the inflammatory
infiltrates were reduced compared with placebo animals
(p  0.05; see Fig 1B). Compared with placebo ani-
mals, we found a decrease in the number of mono-
cytes, T cells, iNOS-positive cells, and astrocyte activa-
tion in MTA-treated animals, and similar amounts of B
cells (p  0.01; see Table 2 and Fig 1C). Finally, APP
staining of damaged axons was decreased in MTA-
treated animals (p  0.01; see Table 2 and Fig 1C).
Methylthioadenosine Ameliorates Ongoing Chronic-
Relapsing Experimental Autoimmune
Encephalomyelitis in DA Rats
Because immunomodulatory therapy starts in patients
after suffering at least the first relapse, we assessed
whether MTA was able to reverse or ameliorate the on-
going autoimmune attack in a chronic-relapsing model
of MS. DA rats immunized with myelin oligodendro-
cyte glycoprotein developed moderate-to-severe
Fig 1. Methylthioadenosine (MTA) administration prevents acute experimental autoimmune encephalomyelitis (EAE). (A) MTA
was administered intraperitoneally after immunization of Lewis rats with myelin basic protein (MBP; day 0). By day 12, placebo
animals (n  27) developed an acute relapse of moderate severity. By contrast, animals treated with MTA (n  20) had almost a
complete prevention of acute EAE. Results are expressed as the mean plus standard deviation of the clinical score (see Subjects and
Methods). Differences between groups were compared with the Mann–Whitney U test. *p  0.05; **p  0.01. Inset shows differ-
ences in day of onset evaluated using Kaplan–Meier curves. Animals treated with MTA have a delayed day of onset (p  0.001,
long-rank test). (B) Histological score of brain and spinal cord from placebo and MTA-treated animals analyzed at the end of the
experiment. MTA-treated animals (black bars) had a lower histological score (see Subjects and Methods) either at the brain or spi-
nal cord sections than placebo animals (white bars) (p  0.05). The number and the extension of the inflammatory infiltrates and
areas or demyelination were reduced in MTA-treated animals. (C) The inflammatory infiltrate in the spinal cord was composed by
macrophages and activated microglial cells (ED1) and T lymphocytes (W3/13), with a decrease in the number of ED1- and W3/
13-positive cells in MTA-treated animals. Enhanced astrocyte activation also was observed in brain sections from placebo-treated
rats compared with animals that received MTA (glial fibrillary acidic protein [GFAP]). By contrast, inducible nitric oxide synthase
(iNOS) was expressed by infiltrating inflammatory cells in spinal cord tissue in the placebo group (iNOS), but was significantly
reduced in the MTA-treated group. Finally, APP expression was present in damaged axons in placebo animals (amyloid -precursor
protein [APP]), but was significantly decreased in MTA-treated animals. Representative immunohistochemical stainings are shown.
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chronic-relapsing EAE with an incidence close to
100%. Animals were randomly assigned to either the
MTA or placebo group at the end of the first clinical
relapse to assess its ability to prevent or ameliorate fur-
ther relapses or chronic diseases. All placebo animals
developed a severe second relapse with a mean clinical
score of 3.12  0.9. By contrast, development of the
second relapse was prevented in 7 of 10 MTA-treated
animals, whereas the other 3 animals developed a sec-
ond but milder relapse (p  0.05; Fig 2A and Table
3). These results are the sum of two different experi-
ments. Histological analysis also showed that MTA-
treated animals have less inflammatory infiltrates with a
smaller amount of demyelinated areas in the brain and
lumbar spinal cord (p  0.05; see Fig 2B). Similar to
the effect of MTA in acute EAE, inflammatory infil-
trates in MTA-treated animals have a decrease of T
cells, macrophages, and iNOS-expressing cells and less
APP axons (p  0.01; Table 4). Thus, MTA was
able to prevent or ameliorate the autoimmune attack to
the brain once it had already started, which mimics the
clinical settings.
Immunomodulatory Effect of Methylthioadenosine in
Rat Peripheral Immune Responses
To assess which was the effect of MTA in the periph-
eral immune response, we evaluated the proliferative
responses against the immunizing antigen, or PHA,
and the cytokine profile in spleen cells from placebo-
and MTA-treated Lewis rats. Myelin basic protein–spe-
cific proliferative response was significantly lower in
MTA-treated animals (p  0.05; Fig 3A). In addition,
MTA also inhibited in a dose-dependent fashion the
proliferation of splenocytes isolated from naive Lewis
rats when stimulated with PHA (p  0.05; see Fig
3B), suggesting that MTA was acting at a critical step
downstream of T-cell receptor (TCR) activation, but
was not antigen-specific.
Gene expression of IL-2, IFN-, TNF-, iNOS, and
IL-10 was investigated by quantitative reverse tran-
scriptase PCR at 9 and 16 days after immunization in
splenocytes from placebo- and MTA-treated Lewis rats.
We found that MTA-treated animals display a suppres-
sion of T helper 1 cell phenotype and an enhanced
expression of the immunosuppressive cytokine IL-10
(see Fig 3C). The downregulation of iNOS in the pe-
ripheral immune cells also correlated with the dimin-
ished iNOS expression by inflammatory cells in the
CNS (see earlier). These observations are in agreement
with our previous findings in the LPS mouse model3
and rule out a nonspecific effect of MTA on overall
gene transcription activity. Interestingly, animals that
received MTA and that were protected from the dis-
ease showed enhanced levels of IL-10 expression by day
9, after immunization, compared with placebo-treated
rats (see Fig 3B). In contrast, in the placebo group,
IL-10 upregulation was observed at day 16, concomi-
tantly with the onset of the spontaneous recovery char-
acteristic of this experimental model.15 In addition, we
also found a significant attenuation in proinflammatory
cytokine gene expression in DA rats treated with MTA
(data not shown).
Immunomodulatory Role of Methylthioadenosine in
Peripheral Blood Mononuclear Cells from Healthy
Subjects and Multiple Sclerosis Patients
To assess whether the immunomodulatory role of
MTA found in rodent EAE was also present in humans
suffering an autoimmune disease, we first studied in
vitro the effect of MTA on T-cell activation and cyto-
kine profile in PBMCs from healthy control subjects.
Activation of the master transcription factor nuclear
factor-B (NF-B) downstream of the TCR allows
antigen-specific proliferation and maturation of lym-
phocytes into effector cells.16,17 NF-B activation in-
volves phosphorylation and subsequent ubiquitin-
mediated degradation of its inhibitor IB.17 We found
that in the presence of MTA, the phosphorylation and
Table 2. Semiquantitative Analysis of Histological Findings in the Prevention Trial (Acute Experimental Autoimmune
Encephalomyelitis in Lewis Rats)
Treatment CNS Region iNOS T Cells B Cells Macrophages APP
MTA Brain Negative    
Cervical cord   Negative  Negative
Thoracic cord Negative  Negative Negative Negative
Lumbar cord Negative    Negative
Placebo Brain a a  a a
Cervical cord a a Negative a a
Thoracic cord a a Negative a a
Lumbar cord a a   a
Differences in the semiquantitative immunohistochemical score were compared between groups using a contingency table and the Kendall’s tau
test for ordinal data.
ap  0.01.
CNS  central nervous system; iNOS  inducible nitric oxide synthase; APP  amyloid -precursor protein; MTA  methylthioadenosine.
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degradation of IB- elicited by PHA stimulation was
almost completely prevented in human PBMCs (Fig
4A). This effect of MTA was dose-dependent (see Fig
4B). Similar observations were made when splenocytes
from naive Lewis rats were stimulated with PHA in the
presence of MTA (see Fig 4C), indicating that no
Table 3. Results of the Treating Trial (Chronic-Relapsing Experimental Autoimmune Encephalomyelitis in DA Rats)
Treatment
Rats,
n
EAE
Incidence,
First
Relapse
EAE
Incidence,
Second
Relapse
EAE Onset
(days)
EAE Maximum
Score
EAE
Cumulative
Score
MTA 10 10/10 3/10 26 6 1.8  1.5 23  20
Placebo 10 10/10 10/10a 21 3a 3.6 1.5a 50 20a
Results are the sum of two different experiments.
ap  0.05, comparison of either methylthioadenosine (MTA)-treated group with placebo-treated group.
EAE  experimental autoimmune encephalomyelitis.
Fig 2. Methylthioadenosine (MTA) treatment ameliorates ongoing chronic-relapsing experimental autoimmune encephalomyelitis
(EAE). (A) Chronic-relapsing EAE was induced in DA rats by immunizing with myelin oligodendrocyte glycoprotein (MOG). Ani-
mals developed the first relapse by day 12 and started to recover from such relapse by day 16. MTA (diamonds) or placebo
(squares) treatment was started after the remission of the first relapse (5 days after the onset of the first relapse, day 18, and were
assessed for the presence of a second relapse in the following 18 days). Placebo animals (n  10) developed a second moderate-to-
severe relapse. By contrast, animals treated with MTA (n  10) were either prevented from developing the second relapse or devel-
oped a mild one. Results are expressed as the mean plus standard deviation of the clinical score (see Subjects and Methods). Differ-
ences between groups were compared with the Mann–Whitney U test. *p  0.05. Inset shows differences in the progression of the
disease between placebo- and MTA-treated animals after the first remission (arrow, day 18) evaluated using Kaplan–Meier curves.
Animals treated with MTA had either no second relapse or a delayed one (p  0.001, long-rank test). Results are the sum of two
independent experiments. (B) Brain and spinal cord from placebo- (white bars) and MTA-treated (black bars) animals were ana-
lyzed at the end of the experiment (day 36). MTA-treated animals had a lower histological score at the brain and lumbar spinal
cord level than placebo animals (p  0.05).
328 Annals of Neurology Vol 60 No 3 September 2006
species-specific differences existed regarding the re-
sponse to MTA treatment. We also have examined
whether the effect of MTA on PHA-mediated IB-
degradation resulted in impaired NF-B activation.
For this, we tested the expression of three NF-B tar-
get genes in human PBMCs that had been pretreated
with MTA and then stimulated with PHA. The up-
regulation in the expression of TNF-, IB-, and
IFN- induced by PHA was significantly attenuated by
MTA treatment (see Fig 4D). No significant toxicity
was appreciated in MTA-treated cells. Together, these
observations also suggest that the immunomodulatory
effects of MTA in the EAE model could be due in part
to the direct interaction of MTA with the NF-B
pathway in inflammatory cells.
MTA is structurally related to adenosine and is able
to interact with adenosine purinergic receptors.18
Adenosine is a potent endogenous modulator of the
inflammatory response,19 including neuroinflammation
in experimental MS.20 Signaling of the antiinflamma-
tory effects of adenosine is mainly attributed to the el-
evation of cyclic adenosine monophosphate (cAMP)
levels and the activation of its downstream effector pro-
tein kinase A (PKA).19 Moreover, adenosine and
cAMP are potent inhibitors of the NF-B pathway
downstream of immunoreceptors.21 These facts, to-
gether with the previously described ability of MTA to
increase cellular cAMP levels,22 made it important to
elucidate whether the currently described effects of
MTA were dependent on the cAMP-PKA pathway. To
this end, PBMCs from healthy subjects were either
pretreated or not pretreated with forskolin, a drug that
activates the cAMP-producing enzyme adenylyl cyclase,
and then stimulated with PHA. In the presence of for-
skolin, the degradation of IB- elicited by PHA was
significantly prevented (see Supplementary Fig S1A).
This is in agreement both with previously described ef-
fects of this PKA activator on T-cell activation and
NF-B signaling19,23 and with what has been observed
in B cells on antigen receptor stimulation.21 When for-
skolin pretreatment was performed in the presence of
the PKA inhibitor H89, the effect of forskolin prevent-
ing PHA-induced IkB- degradation was abrogated
(see Supplementary Fig S1A). Once it was established
that in our experimental model the cAMP-PKA path-
way can modulate NF-B signalling on TCR stimula-
tion, we tested whether the effect of MTA could be
mediated by the elevation of cAMP levels. For this
purpose, PBMCs were pretreated with MTA in the
presence or absence of H89, and then stimulated with
PHA. We observed that the protective effect of MTA
on IB- degradation was preserved when H89 was
used (see Supplementary Fig S1A), implying that the
cAMP effector PKA was not involved in the mecha-
nism of action of MTA.
A well-known biochemical action of MTA is its abil-
ity to interfere with transmethylation reactions either
directly or through the inhibition of S-adenosyl-L-
homocysteine hydrolase.1,2 There is increasing evidence
indicating that methylation reactions, including protein
arginine methylation, play a central role in
T-lymphocyte activation and the cytokine re-
sponse.24–26 Given the key role of NF-B activation in
T-cell function, we wanted to know whether the effects
of MTA on PHA-induced IB- phosphorylation and
degradation could be mimicked by other inhibitors of
transmethylation reactions. This was done by preincu-
bating human PBMCs with either DZA or AdOx, two
different S-adenosyl-L-homocysteine hydrolase inhibi-
tors.27 We observed that, similar to MTA, these two
compounds significantly prevented the phosphorylation
and degradation of IB- in PBMCs (see Supplemen-
tary Fig S1B). Collectively, these observations suggest
that the immunomodulatory effects of MTA are inde-
pendent from the cAMP-PKA pathway and could be
mediated by the suppression of a methylation reaction
involved in NF-B activation.
Finally, we assessed whether the effect of MTA on
Table 4. Semiquantitative Analysis of Histological Findings in the Treating Trial (Chronic-Relapsing Experimental Autoimmune
Encephalomyelitis in DA Rats)
Treatment CNS Region iNOS T Cells B Cells Macrophages APP
MTA Brain   Negative  
Cervical cord Negative  Negative  Negative
Thoracic cord Negative  Negative  
Lumbar cord Negative    Negative
Placebo Brain a a a a a
Cervical cord a  Negative  a
Thoracic cord a  Negative  
Lumbar cord a a  a a
Differences in the semiquantitative immunohistochemical score was compared between groups using a contingency table and Kendall’s tau test
for ordinal data.
ap  0.01.
CNS  central nervous system; iNOS  inducible nitric oxide synthase; APP  amyloid -precursor protein; MTA  methylthioadenosine.
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Fig 4. Methylthioadenosine (MTA) interferes with the activation of the nuclear factor-B (NF-B) pathway in human peripheral
blood mononuclear cells (PBMCs) and rat splenocytes. (A) Effect of MTA treatment on phytohemagglutinin (PHA) induced inhibi-
tor of kappa B (IB-) degradation and Ser-32 IB- phosphorylation. Human PBMCs were pretreated with 100M MTA for 2
hours and then stimulated with PHA (10g/ml) for the indicated periods of time. Control cells (C) received no treatments. Levels
of total IB- and Ser-32 IB- phosphorylated were assessed by Western blotting. Representative blots of three different experi-
ments performed with independent PBMCs preparations are shown. (B) Dose-dependent effect of MTA on PHA induced IB-
degradation and Ser-32 IB- phosphorylation. Human PBMCs were pretreated with different concentrations of MTA for 2 hours
and then stimulated with PHA (10g/ml) for 30 minutes. Control cells (C) received no treatments. Levels of total IB- and
Ser-32 IB- phosphorylated were assessed by Western blotting. Representative blots of three different experiments performed with
independent PBMCs preparations are shown. (C) Effect of MTA treatment on PHA induced IB- degradation and Ser-32 IB-
phosphorylation in rat cells. Splenocytes isolated from naive Lewis rats were pretreated with 100 M MTA for 2 hours and then
stimulated with PHA (10g/ml) for the indicated periods of time. Control cells (C) received no treatments. Levels of total IB-
and Ser-32 IB- phosphorylated were assessed by Western blotting. Representative blots of three different experiments performed
with independent splenocyte preparations are shown. (D) Effect of MTA on the expression of NF-B target genes (tumor necrosis
factor- [TNF-], IB-, and interferon- [IFN-]) in human PBMCs stimulated with PHA. PBMCs were pretreated with
100M MTA for 2 hours and then stimulated with PHA (10g/ml). The expression of TNF- and IB- was measured 6 hours
after PHA stimulation, and IFN- 48 hours after PHA stimulation (time points at which maximal induction was observed). Gene
expression was assessed by real-time polymerase chain reaction. Data are represented as fold change in gene expression levels of
treated groups compared with untreated cells and correspond to three independent experiments performed in triplicate. *p  0.05.
Š Fig 3. Effects of methylthioadenosine (MTA) on the peripheral immune response during experimental autoimmune encephalomyelitis
(EAE). (A) Myelin basic protein–specific (MBP; 10g/ml) and mitogen (5g/ml phytohemagglutinin [PHA]) proliferative response
of splenocytes from placebo- (white bar) or MTA-treated (black bar) Lewis rats obtained at time of death. Data are means 
standard error of the mean (SEM) of two independent experiments performed in triplicate. *p  0.05. (B) MTA dose dependently
inhibits the proliferation of splenocytes isolated from naive Lewis rats and stimulated with PHA (5g/ml). Splenocytes were cultured
for 2 hours with MTA before PHA addition. Data are means  SEM of two independent experiments performed in triplicate. *p
 0.05 with respect to cells treated with PHA only; **p  0.05 with respect to cells treated with 50M MTA. (C) Gene expres-
sion profile of cytokines and inducible nitric oxide synthase (iNOS) assayed by quantitative reverse transcriptase-polymerase chain
reaction (RT-PCR) in the spleen of placebo- (white bars) and MTA-treated (black bars) Lewis rats at days 9 and 16 after immu-
nization. Data are expressed as fold change in gene expression levels in the treated groups compared with untreated controls. *p 
0.05. IFN  interferon; IL  interleukin; TNF  tumor necrosis factor.
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T-cell activation was preserved in PBMCs obtained
from patients with MS. First, we observed that when
compared with healthy control subjects, unstimulated
PBMCs from 7 of 13 MS patients studied showed re-
duced levels of IB- protein and enhanced IB-
phosphorylation (Fig 5A). This is in agreement with a
recent publication in which PBMCs from patients with
relapsing MS showed enhanced NF-B DNA-binding
activity.28 Subsequently, we observed that treatment of
PBMCs obtained from those MS patients with low lev-
els of IB- (n  7) with increasing concentrations of
MTA resulted in a dose-dependent upregulation of
IB- protein levels and the concomitant inhibition of
IB- phosphorylation. Figure 5B shows two represen-
tative cases, and a similar response was obtained with
PBMCs from the remaining five MS patients who dis-
played reduced levels of IB- (data not shown). MTA
did not affect the IB- levels in PBMCs from MS
patients with normal basal levels of IB- (data not
shown). In summary, these observations indicate that
MTA has an immunomodulatory effect both in ro-
dents and humans, and that such effect is also present
in immune cells from MS patients.
Discussion
We have shown that administration of the naturally
occurring nucleoside MTA reduces the development of
clinical signs in two models of EAE. Moreover, MTA
treatment resulted in the prevention of acute EAE, but
more importantly in the amelioration of the disease in
the chronic-relapsing EAE model, which more closely
resembles the clinical situation found in humans. Neu-
ral tissue damage was attenuated and inflammatory in-
filtrates were reduced in those animals that received
MTA.
The mechanism of action of MTA is likely to be
multifaceted. On one hand, MTA is known to exert
direct antioxidant effects in vivo,29 and an ability to
attenuate the production of reactive oxygen species has
been demonstrated to participate in the therapeutic ef-
fects of neuroprotective compounds in EAE models.30
We believe, however, that more specific immuno-
modulatory effects are involved in the mechanism of
action of MTA in EAE. We have previously demon-
strated that MTA is a potent modulator of the innate
immune response, preventing death in LPS-challenged
mice.3 Subsequently, it was shown by others that in
vitro MTA treatment inhibited cytokine gene expres-
sion in isolated T lymphocytes and Jurkat T cells after
TCR activation.25,31 Here, we have provided evidence
showing that MTA can modulate T-cell activation and
TCR-conveyed signaling in vivo and in vitro, including
the downregulation of proinflammatory cytokines and
the enhancement of IL-10 production, effects that are
likely related to the beneficial outcome of MTA ad-
ministration in EAE.30,32 Furthermore, our data sug-
gest that modulation of NF-B–mediated signaling
may be central to the effects of this nucleoside on
T-cell activation and cytokine production.33 Indeed,
we have shown that MTA inhibited the degradation of
IB- on TCR activation in human PBMCs. On cel-
lular stimulation (as occurs after TCR engagement),
IB proteins become phosphorylated by the IB kinase
complex, and these phosphorylations trigger the subse-
quent degradation of IB proteins, which ultimately
results in the release and nuclear translocation of
NF-B where it regulates the expression of its target
genes.17 We observed that MTA prevented the phos-
phorylation of IB- in PHA-stimulated human PB-
MCs, suggesting that one site of action of MTA could
be located between the TCR and the IB kinase com-
plex. Interestingly, we also observed that PBMCs ob-
tained from a significant number of MS patients dis-
played reduced IB- protein levels and enhanced
IB- phosphorylation, suggesting that basal activation
of the NF-B pathway may be present in PBMCs from
MS patients, as recently reported by others.28 Cur-
rently, however, we do not have an explanation for the
different levels of IB- protein found among the MS
patients tested. Nevertheless, what we have consistently
Fig 5. Inhibitor of kappa B (IB-) and phospho-IB- lev-
els in peripheral blood mononuclear cells (PBMCs) from
healthy subjects and multiple sclerosis (MS) patients and effect
of methylthioadenosine (MTA) treatment. (A) Levels of IB-
and P-Ser-32 IB- phosphorylation in PBMCs from MS
patients and healthy control subjects. PBMCs were obtained
under the same conditions from 3 healthy subjects (C1-3) and
10 MS patients (P1-10) and were analyzed by Western blot-
ting. Equal loading was demonstrated using an antibody
against Actin. (B) Dose-dependent effect of MTA levels of
IB- and P-Ser-32 IB- in PBMCs obtained from two
MS patients (P1 and P2) treated in vitro with the indicated
concentrations of MTA for 2 hours. Equal loading was dem-
onstrated using an antibody against actin. Representative blots
are shown.
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observed is that MTA treatment of PBMCs from those
MS patients with reduced IB- levels results in the
attenuation of IB- phosphorylation and the recovery
of IB- protein levels. Together, these data suggest
that MTA has an immunomodulatory function and
that, at least ex vivo, MTA can reverse the proinflam-
matory status of immune cells from MS patients.
Our findings also indicate that the effects of MTA
are independent from the cAMP-PKA pathway, which
is central to the antiinflammatory mechanism of the
MTA analogue adenosine acting through the A2A re-
ceptors.19 Indeed, adenosine recently has been shown
to suppress the activation of NF-B in B lymphocytes
through inhibition of IB- phosphorylation; however,
contrary to our observations with MTA, these effects
were dependent on PKA activation.21 Nevertheless, the
interaction of MTA with other adenosine receptors
that mainly convey cAMP-independent immunomodu-
latory signals, such as the A1 receptor, cannot be dis-
carded.18
Lymphocytes appear to be highly dependent on
transmethylation reactions for efficient activation and
function.26,34 As mentioned previously, one of the
most prominent biochemical actions of MTA is the in-
hibition of methylation reactions.1,2 Interference with
arginine methylation at the amino terminus of the Nu-
clear Factor of Activated T Cells (NFAT) cofactor
NIP45 has been proposed to mediate the inhibitory ef-
fect of MTA on cytokine gene expression in T lym-
phocytes.25 Our observations indirectly suggest that ac-
tivation of the NF-B pathway on TCR stimulation
also can be dependent on de novo methylation reac-
tion. Supporting this notion is the finding that MTA
effects on IB- phosphorylation and degradation were
mimicked by DZA and AdOx, two different inhibitors
of methylation reactions. The molecular pathway link-
ing the TCR to NF-B activation is complex, and so
far is not completely known.16,17 Of the many com-
ponents of the cascade from the TCR to IB kinase
that could be potential targets of MTA, one likely can-
didate could be Vav-1, recently reported to undergo
arginine methylation on T-cell activation.35 Neverthe-
less, although suggestive, our in vitro experiments using
transmethylation inhibitors do not allow us to con-
clude that the effects of MTA in the two models of
EAE would be mediated exclusively through the im-
pairment of a methylation reaction.
In our study, we focused on the role of MTA in
T-cell activation. However, MTA might also have a
role in the CNS innate immune system, mainly in mi-
croglia cells. In recent years, microglia have gained in-
creasing attention in MS research, but also in the over-
all spectrum of neurodegenerative diseases, because
they are the resident effector cells of the immune sys-
tem, which might imply involvement in disease patho-
genesis. Microglia have a dual role in the CNS. Micro-
glia might amplify the effects of inflammation in the
CNS and mediate cell degeneration. They might also
have a protective effect of the CNS.36 Recent evidences
suggest that activated microglia might have a neuropro-
tective function (eg, by releasing neurotrophic factors
or scavenging toxic compounds).37,38 Because micro-
glia need to be activated to exert their functions, we
can hypothesize that some of the pathways involved in
this process can be targeted by MTA, and thus modu-
late microglia activity and influence EAE outcome.
MTA is a well-tolerated drug, devoid of the un-
wanted effects of other methyltransferase inhibitors. It
has been administered previously in both acute and
chronic experimental models of liver injury and sys-
temic inflammation, showing efficacy and a safe pro-
file,3 with an ID50 of 2.9 0.4gm/kg (intramuscular)
in rats.29 In humans, MTA is also well tolerated.
Twenty-eight individuals (21–48 years old) were
treated with 100mg every 8 hours for 3 days or
600mg/day for 1 month without signs of toxicity.39,40
Thus, MTA would be an excellent candidate drug to
be tested in patients with MS because it is safe and is
effective in preventing brain autoimmune attack. In
addition, because MTA may have a pleiotropic mech-
anism of action in preventing T-cell activation, which
is a critical step in autoimmune diseases, but without
inducing immunosuppression, it appears an ideal can-
didate for combining with other immunomodulatory
drugs to obtain a higher efficacy in stopping relapses
and disease progression without increasing side effects.
The immunomodulatory properties of MTA also pro-
vide a rationale for testing MTA in other autoimmune
diseases in which the T-cell activation process plays a
critical role, such as type 1 diabetes and rheumatoid
arthritis.
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